Advertisement

Involvement of hypoxia-inducing factor-1α-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion.

Open AccessPublished:December 01, 2016DOI:https://doi.org/10.1074/jbc.A116.708933
      VOLUME 283 (2008) PAGES 15807–15815
      This article has been withdrawn by authors Ming-Tsan Lin, I-Hsin Kuo, Cheng-Chi Chang, Chia-Yu Chu, Been-Ren Lin, and Min-Liang Kuo. The same images were used to represent different experimental conditions. In Fig. 1A, lanes 2 and 4 of the HIF-1α DNA gel were duplicated. The HIF-1α DNA gel from Fig. 1A was reused in Fig. 1E in the HIF-1α rCyr61 panel. The GAPDH DNA gel from Fig. 1A was reused in Fig. 1E as GAPDH rCyr61 and IGF-1 panels, Fig. 5A as GAPDH, and Fig. 6B as input, left panel. The HIF-1β immunoblot from Fig. 1A was reused in Fig. 1B as HIF-1β, AGS and TSGH panels, Fig. 1D as HIF-1β, N87 panel, Fig. 1F as HIF-1β, rCyr61 panel, and Fig. 3D as HIF-1β. The tubulin immunoblot from Fig. 1A was reused in Fig. 5B as tubulin, lower panel, and reused in Fig. 5E as tubulin, left panel. In Fig. 1C, lanes 1 and 2 of the HIF-1α immunoblot were reused in lanes 5 and 6. In Fig. 1D, the HIF-1α immunoblot from the N87 panel was reused in Fig. 1F in the HIF-1α IGF-1 panel. In Fig. 1E, lanes 2 and 3 of the HIF-1α DNA gel from the rCyr61 panel were duplicated in lanes 5 and 6 of the same panel. Also in Fig. 1E, the HIF-1α DNA gel from the CoCl2 panel was reused in the IGF-1 panel as HIF-1α. In Fig. 1F, lanes 4 and 5 were duplicated in the HIF-1β immunoblot from the CoCl2 panel. The HIF-1β immunoblot from the IGF-1 panel in Fig. 1F was reused in Fig. 3A as tubulin. In Fig. 1G, lanes 1 and 2 of the tubulin immunoblot, left panel, was reused in lanes 3 and 4 of the same panel. In Fig. 2A, lanes 2 and 4 of the HIF-1α immunoblot and lanes 3 and 4 of the HIF-1β immunoblot from the CoCl2 panel were duplicated. In Fig. 2C, lanes 1 and 2 of the HIF-1β immunoblot were duplicated in lanes 4 and 5, lanes 7 and 8, lanes 9 and 10, and lanes 11 and 12. Also, in the same panel, lanes 3 and 6 were duplicated. In Fig. 3A, lanes 4 and 5 of the HIF-1β immunoblot were duplicated. Also in the same figure, lane 1 of the p-AKT immunoblot was duplicated in lanes 3 and 5, and lane 2 of the AKT immunoblot was duplicated in lane 5. The AKT immunoblot from Fig. 3A was also reused in Fig. 3D as 4E-BP1. In Fig. 3B, lane 1 of the p-AKT immunoblot was reused in lanes 5 and 6, and lane 1 of the AKT immunoblot was reused in lane 6. In Fig. 3D, lane 1 of the HIF-1α immunoblot was reused in lane 6, and lane 1 of the p-p70S6K immunoblot was reused in lane 5. The graphs in Fig. 4A were duplicated. In Fig. 5A, lane 1 of the c-MET DNA gel was reused in lanes 5 and 6, and lane 2 of the same gel was reused in lane 4. Also in Fig. 5A, lanes 1–3 of the AMF gel were reused in lanes 4–6. In Fig. 5C, lane 1 of the PAI-1 DNA gel was reused in lane 2, and lane 1 of the GAPDH DNA gel was reused in lane 2. In Fig. 6A, lanes 1 and 4 of the tubulin immunoblot were duplicated. Lane 2 of the PAI-1 DNA gel from Fig. 6B, left panel, was reused in lanes 2 and 3 of the PAI-1 DNA gel, right panel. In Fig. 6B, lanes 1 and 4 of the input DNA gel, right panel, were duplicated.